FR2596986A1 - Use of lactoferrin in cosmetic preparations acting against free radicals - Google Patents
Use of lactoferrin in cosmetic preparations acting against free radicals Download PDFInfo
- Publication number
- FR2596986A1 FR2596986A1 FR8605183A FR8605183A FR2596986A1 FR 2596986 A1 FR2596986 A1 FR 2596986A1 FR 8605183 A FR8605183 A FR 8605183A FR 8605183 A FR8605183 A FR 8605183A FR 2596986 A1 FR2596986 A1 FR 2596986A1
- Authority
- FR
- France
- Prior art keywords
- lactoferrin
- free radicals
- cosmetic composition
- fact
- acting against
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010063045 Lactoferrin Proteins 0.000 title claims abstract description 13
- 102000010445 Lactoferrin Human genes 0.000 title claims abstract description 13
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title claims abstract description 13
- 235000021242 lactoferrin Nutrition 0.000 title claims abstract description 13
- 229940078795 lactoferrin Drugs 0.000 title claims abstract description 13
- 239000002537 cosmetic Substances 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 230000032683 aging Effects 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 206010061218 Inflammation Diseases 0.000 claims abstract 2
- 230000004054 inflammatory process Effects 0.000 claims abstract 2
- 150000003254 radicals Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 7
- 206010041303 Solar dermatitis Diseases 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 abstract 1
- 231100000321 erythema Toxicity 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- -1 lipid hydroperoxides Chemical class 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
Description
UTILISATION DE LA LACTOFERRINE DANS DES PREPARATIONS COSMETIQUES ANTI
RADICAUX LIBRES.USE OF LACTOFERRIN IN ANTI COSMETIC PREPARATIONS
FREE RADICALS.
La présente invention est relative à l'utilisation en cosm6tique de la lactoferrine en tant qu'agent anti-radicaux libres, ainis qu'aux compositions renfermant cette substance
L'oxygène est indispensoble à la respiration des 6tres vivants aérobies
Cependant, il peut également présenter un caractère toxique lié à la présence des radicaux libres qu'il engendre.The present invention relates to the cosmetic use of lactoferrin as an anti-free radical agent, as well as to the compositions containing this substance.
Oxygen is essential for the respiration of aerobic living beings
However, it can also present a toxic character linked to the presence of the free radicals which it generates.
En effet, l'oxygène peut être réduit en radical superoxyde selon la reaction
qui est réalisée chez toutes les cellules aérobies1 et plus particuliere- ment encore chez les cellules responsables de la phagocytose telles que les neutrophiles. les monocytes, les macrophages et les éosinophiles.Indeed, oxygen can be reduced to superoxide radical according to the reaction
which is performed in all aerobic cells1 and more particularly in cells responsible for phagocytosis such as neutrophils. monocytes, macrophages and eosinophils.
C'est la raison pour laquelle ce radical est produit en quantité importante dans les tissus inflammés.This is the reason why this radical is produced in large quantities in inflamed tissues.
Or ce radical, peu réactif en solution aqueuse, peut subir une réaction de dismutation donnant naissance à du peroxyde d'hydrogène :
Mais, en présence de traces de fer, il peut également réduire l'ion Fe@@
Les ions Fe2+ ainsi produits peuvent denner Ileu à la réaction de fenton qui produit le radical hydroxyle :
Le bilan de ces deux dernières réactions étant connu sous le nom de réaction
Haber - Weiss :
Haber - Weiss:
On constate donc que le fer joue un rôle essentiel dans l'apparition du radical hydroxyle. (pour plus de renseignements sur ce sujet, voir l'article de HALLIWELL et GUTTERIDGE 1984, Bicohem. J. 219 : 1 - 14).It is therefore found that iron plays an essential role in the appearance of the hydroxyl radical. (for more information on this subject, see the article by HALLIWELL and GUTTERIDGE 1984, Bicohem. J. 219: 1 - 14).
Or, le radical hydroxyle peut provoquer des dégats très important dans l'organisme. En effet. il est tellement réactif que, dans une cellule vivante, il réagit immédiatement avec la premi8re moécule bislogique présente dans son voisinage.However, the hydroxyl radical can cause very significant damage in the body. Indeed. it is so reactive that, in a living cell, it reacts immediately with the first biologic molecule present in its vicinity.
En particulier, il est capable de casser des brias d'ADN en réagissant avec ses bases et donc de provoquer des mutatiens altérant le patrimoine génétique de la cellule.In particular, it is capable of breaking DNA brias by reacting with its bases and therefore causing mutatians altering the genetic heritage of the cell.
Le radical hydroxyle, contrairement à H2O2 ou au radical 02@ est égolement capable de provoquer une peroxydation das acides gras insaturés
Les hydroperoxydes lipidiques ainsi obtenus demeurent stables jusqu'au moment où ils entrent en contact avec des pétaux de transition, tels que le fer. Il se produit alors une décomposition très complexe de ces hydroperoxydes lipidiques conduisant à la production d'aldéhydes cytotoxiques, de gaz et finalement, à la détérioration des membranes plasmiques. De plus ces produits de décomposition forment des mélanges complexes colorés en brun, connus sous le nom de lipofuscine, dont la présence a été décelée, en particulier, au niveau du derme de persoanes agées (CARLISLE et MONTAGNA 1979, Journal of Investigature Dermatoiogy,
J. 73 : 54 - 58).The hydroxyl radical, unlike H2O2 or the 02 @ radical, is also capable of causing peroxidation of unsaturated fatty acids
The lipid hydroperoxides thus obtained remain stable until they come into contact with transition petals, such as iron. A very complex decomposition of these lipid hydroperoxides then takes place, leading to the production of cytotoxic aldehydes, of gases and finally, to the deterioration of the plasma membranes. In addition, these decomposition products form complex mixtures colored in brown, known under the name of lipofuscin, the presence of which has been detected, in particular, in the dermis of elderly persoans (CARLISLE and MONTAGNA 1979, Journal of Investigature Dermatoiogy,
J. 73: 54-58).
D'autre part, il a été également démontré que les radicaux libres peuvent être responsables d'une détérioration de l'acide hyaluronique conduisant à sa dépolymérisation et à une diminution de sa viscosité.On the other hand, it has also been shown that free radicals can be responsible for a deterioration of hyaluronic acid leading to its depolymerization and a decrease in its viscosity.
Connaissant l'importance de cette substance dans le maintien de la teneur hydrique et des propriétés mécaniques du derme, on conçoit le rôle joué par les radicaux libres dans le vieillissement de la peau.Knowing the importance of this substance in maintaining the water content and mechanical properties of the dermis, we can understand the role played by free radicals in the aging of the skin.
Pour plus de détails concernant les radicaux libres et leur action nocive sur l'organisme, il conviendra de se refermer à l'article de HALLIWELL 1984,
Medical Biology 62 : 71 - 77.For more details concerning free radicals and their harmful action on the organism, it will be advisable to close in the article of HALLIWELL 1984,
Medical Biology 62: 71-77.
Le fer présent à l'état de traces dans toutes les cellules sert donc d'intermédiaire aux transferts d'électrons responsables de la propagation des radicaux libres qui sont à l'origine de la détérioration d'un grand nombre de molécules et de structures organiques. Le piègeage de ce fer pourrait donc jouer un ôle important dans l'inhibition de la production de ces radicaux libres.The trace iron present in all cells therefore serves as an intermediary for the transfer of electrons responsible for the propagation of free radicals which are at the origin of the deterioration of a large number of molecules and organic structures. . The trapping of this iron could therefore play an important role in the inhibition of the production of these free radicals.
Or, il existe dans le lait une protéine, la lactoferrine, capable de remplir cette fonction. En effet, chaque molécule de cette substance peut fixer deux atomes de fer qui deviennent donc indisponibles pour les réactions intervenant dans la production des radicaux libres.However, there exists in milk a protein, lactoferrin, capable of fulfilling this function. Indeed, each molecule of this substance can fix two iron atoms which therefore become unavailable for the reactions involved in the production of free radicals.
La lactoferrine peut être extraite et purifiée à partir du lait au moyen de techniques classiques de la bIochimie preparative telies que des précipitations au sulfate d'ammonium, des ultrafiltrations ou des chrG a- tographies d'échange d'ions.Lactoferrin can be extracted and purified from milk using standard preparative biochemistry techniques such as ammonium sulphate precipitation, ultrafiltration or ion exchange chromatography.
La présente invention a donc pour objet l'utilisation de la lactoferrine dans des préparations cosmétiques anti-radicaux libres. Cette protéine peut être utilisée seule ou en association avec d'autres substances possédant des propriétés de piègeurs de radicaux libres ou d'antioxydants telles que les tocophérols, le carotène .... (cette liste n'étant pas limitative).The present invention therefore relates to the use of lactoferrin in anti-free radical cosmetic preparations. This protein can be used alone or in combination with other substances having properties of free radical scavengers or antioxidants such as tocopherols, carotene .... (this list is not exhaustive).
Elle peut être employée en solution aqueuse, dans des émulsions ou dans des phases lamellaires lipidiques dispersées du type liposomes.It can be used in aqueous solution, in emulsions or in dispersed lipidic lamellar phases of the liposome type.
De telles préparations trouvent leur application chaque fois que des radicaux libres sont produits en quantité importante. C'est le cas, en particulier, dans les tissus inflammés envahis par des neutrophiles qui, comme nous l'avons vu précédemment, sont de grands producteurs de radicaux libres. Mais c'est également le cas pour les tissus soumis 3 une dose excessive de rayons ultrat-violets en l'absence de protection.Such preparations find their application whenever free radicals are produced in large quantities. This is the case, in particular, in inflamed tissues invaded by neutrophils which, as we have seen above, are large producers of free radicals. But this is also the case for tissues subjected to an excessive dose of ultraviolet rays in the absence of protection.
En effet, ces rayonnements sont suffisemment énergétiques pour produire des radicaux libres qui contributent à l'apparition de l'érythème solaire.Indeed, these radiations are sufficiently energetic to produce free radicals which contribute to the appearance of solar erythema.
Mais de tels traitements peuvent 6galement être utilisés à titre préventif dans le cadre plus général de la lutte contre le vieillissement de la peau. However, such treatments can also be used as a preventive measure in the more general context of the fight against aging of the skin.
Claims (7)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8605183A FR2596986B1 (en) | 1986-04-11 | 1986-04-11 | USE OF LACTOFERRIN IN COSMETIC, FREE ANTIRADICAL PREPARATIONS |
| FR8900638A FR2641696B2 (en) | 1986-04-11 | 1989-01-18 | USE OF A MIXTURE CONTAINING LACTOFERRIN IN FREE ANTI-RADICAL COSMETIC PREPARATIONS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8605183A FR2596986B1 (en) | 1986-04-11 | 1986-04-11 | USE OF LACTOFERRIN IN COSMETIC, FREE ANTIRADICAL PREPARATIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2596986A1 true FR2596986A1 (en) | 1987-10-16 |
| FR2596986B1 FR2596986B1 (en) | 1988-09-23 |
Family
ID=9334134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8605183A Expired FR2596986B1 (en) | 1986-04-11 | 1986-04-11 | USE OF LACTOFERRIN IN COSMETIC, FREE ANTIRADICAL PREPARATIONS |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2596986B1 (en) |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0313305A2 (en) * | 1987-10-22 | 1989-04-26 | The Procter & Gamble Company | Photoprotection compositions comprising chelating agents |
| EP0313347A2 (en) * | 1987-10-22 | 1989-04-26 | The Procter & Gamble Company | Photoprotection compositions comprising sorbohydroxamic acid and an anti-inflammatory agent |
| EP0313302A2 (en) * | 1987-10-22 | 1989-04-26 | The Procter & Gamble Company | Photoprotection compositions comprising sorbohydroxamic acid |
| JPH01135726A (en) * | 1987-11-19 | 1989-05-29 | Nonogawa Shoji:Kk | Skin external preparation |
| US4992264A (en) * | 1988-01-29 | 1991-02-12 | Michel Diot | Novel cosmetic compositions containing an extract of the aerial parts of Cichorium intybus L |
| FR2652001A1 (en) * | 1989-09-20 | 1991-03-22 | Andary Claude | Dermato-cosmetic composition based on rosmarinic acid, possessing properties of a sunscreen agent and anti-inflammatory agent |
| EP0504040A1 (en) * | 1991-03-13 | 1992-09-16 | L'oreal | Use of lactoferrin to protect hair keratin from atmospheric aggressions, particularly light, and process for protecting the hair using this compound |
| EP0505841A2 (en) * | 1991-03-25 | 1992-09-30 | Miles Inc. | Analgesic composition containing beta-carotene |
| FR2685202A1 (en) * | 1991-12-24 | 1993-06-25 | Sederma Sa | Novel method of pharmaceutical and cosmetic treatment for the regulation of seborrhoea, acne and the cutaneous flora |
| FR2706301A1 (en) * | 1993-06-09 | 1994-12-23 | Clarins | Cosmetic night preparation intended for combating skin aging |
| EP0657520A1 (en) * | 1992-08-07 | 1995-06-14 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
| EP0729750A1 (en) * | 1994-12-28 | 1996-09-04 | L'oreal | Use of an interleukin-1 antagonist and/or alpha-TNF antagonist in a cosmetic, pharmaceutical or dermatological composition, and the composition therefrom, possibly used in combination with a histamine antagonist |
| WO1998044940A1 (en) * | 1997-04-10 | 1998-10-15 | Agennix, Inc. | Use of lactoferin in the treatment of allergen induced disorders |
| EP1055720A2 (en) * | 1999-05-28 | 2000-11-29 | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | Compositions for stabilizing oxygen-labile species |
| WO2002015861A1 (en) * | 2000-08-23 | 2002-02-28 | Beiersdorf Ag | Substances for inducing and intensifying the tanning mechanisms of the skin and cosmetic or dermatological preparations which contain said substances |
| WO2005016372A1 (en) * | 2003-03-25 | 2005-02-24 | Advitech Solutions Inc. | Compositions comprising polymetal-binding proteins and plant extracts for reducing free radicals |
| US7897144B2 (en) | 2001-02-28 | 2011-03-01 | Johnson & Johnson Comsumer Companies, Inc. | Compositions containing legume products |
| US7985404B1 (en) | 1999-07-27 | 2011-07-26 | Johnson & Johnson Consumer Companies, Inc. | Reducing hair growth, hair follicle and hair shaft size and hair pigmentation |
| US8039026B1 (en) | 1997-07-28 | 2011-10-18 | Johnson & Johnson Consumer Companies, Inc | Methods for treating skin pigmentation |
| US8093293B2 (en) | 1998-07-06 | 2012-01-10 | Johnson & Johnson Consumer Companies, Inc. | Methods for treating skin conditions |
| US8106094B2 (en) | 1998-07-06 | 2012-01-31 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for treating skin conditions |
| US8431550B2 (en) | 2000-10-27 | 2013-04-30 | Johnson & Johnson Consumer Companies, Inc. | Topical anti-cancer compositions and methods of use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2487642A2 (en) * | 1980-07-31 | 1982-02-05 | Bel Fromageries | Sepn. of protein fractions esp. from milk prods. - using membrane ultrafiltration, exclusion chromatography and ion exchange resins |
-
1986
- 1986-04-11 FR FR8605183A patent/FR2596986B1/en not_active Expired
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2487642A2 (en) * | 1980-07-31 | 1982-02-05 | Bel Fromageries | Sepn. of protein fractions esp. from milk prods. - using membrane ultrafiltration, exclusion chromatography and ion exchange resins |
Non-Patent Citations (1)
| Title |
|---|
| BIOCHEMICAL JOURNAL, vol. 199, 1981, pages 259-261, The Biochemical Society, GB; J.M.C. GUTTERIDGE et al.: "Inhibition of lipid peroxidation by the iron-binding protein lactoferrin * |
Cited By (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0496433A3 (en) * | 1987-10-22 | 1994-05-18 | Procter & Gamble | Photoprotection compositions comprising chelating agents |
| EP0313347A2 (en) * | 1987-10-22 | 1989-04-26 | The Procter & Gamble Company | Photoprotection compositions comprising sorbohydroxamic acid and an anti-inflammatory agent |
| EP0313302A2 (en) * | 1987-10-22 | 1989-04-26 | The Procter & Gamble Company | Photoprotection compositions comprising sorbohydroxamic acid |
| EP0313347A3 (en) * | 1987-10-22 | 1989-07-26 | The Procter & Gamble Company | Photoprotection compositions comprising sorbohydroxamic acid and an anti-inflammatory agent |
| EP0313302A3 (en) * | 1987-10-22 | 1989-08-09 | The Procter & Gamble Company | Photoprotection compositions comprising sorbohydroxamic acid |
| EP0313305A3 (en) * | 1987-10-22 | 1990-02-07 | The Procter & Gamble Company | Photoprotection compositions comprising chelating agents |
| US5487884A (en) * | 1987-10-22 | 1996-01-30 | The Procter & Gamble Company | Photoprotection compositions comprising chelating agents |
| EP0313305A2 (en) * | 1987-10-22 | 1989-04-26 | The Procter & Gamble Company | Photoprotection compositions comprising chelating agents |
| EP0496434A3 (en) * | 1987-10-22 | 1994-05-18 | Procter & Gamble | Photoprotection compositions comprising chelating agents |
| JPH01135726A (en) * | 1987-11-19 | 1989-05-29 | Nonogawa Shoji:Kk | Skin external preparation |
| US4992264A (en) * | 1988-01-29 | 1991-02-12 | Michel Diot | Novel cosmetic compositions containing an extract of the aerial parts of Cichorium intybus L |
| FR2652001A1 (en) * | 1989-09-20 | 1991-03-22 | Andary Claude | Dermato-cosmetic composition based on rosmarinic acid, possessing properties of a sunscreen agent and anti-inflammatory agent |
| FR2673839A1 (en) * | 1991-03-13 | 1992-09-18 | Oreal | USE OF LACTOFERRIN FOR THE PROTECTION OF HAIR KERATIN AGAINST ATMOSPHERIC AGGRESSIONS, IN PARTICULAR LIGHT, AND HAIR PROTECTION METHOD USING THE SAME. |
| EP0504040A1 (en) * | 1991-03-13 | 1992-09-16 | L'oreal | Use of lactoferrin to protect hair keratin from atmospheric aggressions, particularly light, and process for protecting the hair using this compound |
| EP0505841A3 (en) * | 1991-03-25 | 1993-07-28 | Miles Inc. | Analgesic composition containing beta-carotene |
| EP0505841A2 (en) * | 1991-03-25 | 1992-09-30 | Miles Inc. | Analgesic composition containing beta-carotene |
| FR2685202A1 (en) * | 1991-12-24 | 1993-06-25 | Sederma Sa | Novel method of pharmaceutical and cosmetic treatment for the regulation of seborrhoea, acne and the cutaneous flora |
| EP0657520A1 (en) * | 1992-08-07 | 1995-06-14 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
| EP0657520A4 (en) * | 1992-08-07 | 1996-02-07 | Morinaga Milk Industry Co Ltd | ANTIOXIDANE. |
| FR2706301A1 (en) * | 1993-06-09 | 1994-12-23 | Clarins | Cosmetic night preparation intended for combating skin aging |
| EP0729750A1 (en) * | 1994-12-28 | 1996-09-04 | L'oreal | Use of an interleukin-1 antagonist and/or alpha-TNF antagonist in a cosmetic, pharmaceutical or dermatological composition, and the composition therefrom, possibly used in combination with a histamine antagonist |
| WO1998044940A1 (en) * | 1997-04-10 | 1998-10-15 | Agennix, Inc. | Use of lactoferin in the treatment of allergen induced disorders |
| US8039026B1 (en) | 1997-07-28 | 2011-10-18 | Johnson & Johnson Consumer Companies, Inc | Methods for treating skin pigmentation |
| US8093293B2 (en) | 1998-07-06 | 2012-01-10 | Johnson & Johnson Consumer Companies, Inc. | Methods for treating skin conditions |
| US8106094B2 (en) | 1998-07-06 | 2012-01-31 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for treating skin conditions |
| EP1055720A2 (en) * | 1999-05-28 | 2000-11-29 | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | Compositions for stabilizing oxygen-labile species |
| EP1055720A3 (en) * | 1999-05-28 | 2001-03-07 | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | Compositions for stabilizing oxygen-labile species |
| US7985404B1 (en) | 1999-07-27 | 2011-07-26 | Johnson & Johnson Consumer Companies, Inc. | Reducing hair growth, hair follicle and hair shaft size and hair pigmentation |
| WO2002015861A1 (en) * | 2000-08-23 | 2002-02-28 | Beiersdorf Ag | Substances for inducing and intensifying the tanning mechanisms of the skin and cosmetic or dermatological preparations which contain said substances |
| US8431550B2 (en) | 2000-10-27 | 2013-04-30 | Johnson & Johnson Consumer Companies, Inc. | Topical anti-cancer compositions and methods of use thereof |
| US7897144B2 (en) | 2001-02-28 | 2011-03-01 | Johnson & Johnson Comsumer Companies, Inc. | Compositions containing legume products |
| WO2005016372A1 (en) * | 2003-03-25 | 2005-02-24 | Advitech Solutions Inc. | Compositions comprising polymetal-binding proteins and plant extracts for reducing free radicals |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2596986B1 (en) | 1988-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2596986A1 (en) | Use of lactoferrin in cosmetic preparations acting against free radicals | |
| US5985296A (en) | Complexes of gamma-cyclodextrin and retinol or retinol derivatives, processes for their preparation and their use | |
| Bustamante et al. | Role of melanin as a scavenger of active oxygen species | |
| López-Revuelta et al. | Membrane cholesterol contents influence the protective effects of quercetin and rutin in erythrocytes damaged by oxidative stress | |
| Martensson et al. | Glutathione deficiency decreases tissue ascorbate levels in newborn rats: ascorbate spares glutathione and protects. | |
| Mordente et al. | Antioxidant properties of 2, 3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1, 4-benzoquinone (idebenone) | |
| De La Paz et al. | Lipid peroxidation in rod outer segments. Role of hydroxyl radical and lipid hydroperoxides. | |
| Hasegawa et al. | Design and synthesis of polymeric hydrogen sulfide donors | |
| AU759052B2 (en) | Topical compositions for enhancing glutathione production | |
| AU663542B2 (en) | Active oxygen scavenger | |
| EA032076B1 (en) | Derivatives obtained from hyaluronic acid and carnosine | |
| Müller et al. | Hydroxyl radical damage to DNA sugar and model membranes induced by anthralin (dithranol) | |
| WO1998031336A1 (en) | Use of an extract of the genus adansonia | |
| Kozina et al. | Antioxidant properties of geroprotective peptides of the pineal gland | |
| FR2641696A2 (en) | Use of a mixture containing lactoferrin in cosmetic anti-free-radical preparations | |
| FR2655054A1 (en) | Cell-protecting agents containing curcuminoids | |
| CN114224778B (en) | Schizophyllum commune polysaccharide composition and preparation method and application thereof | |
| EP1753781A1 (en) | Peptides or peptidic conjugate derivatives of msh and the use thereof for cosmetically fighting against canities | |
| EP0881898A1 (en) | Composition for preventing ageing of the skin | |
| WO2004078789A1 (en) | Novel agent for stimulating the release of beta-endorphins, cosmetic and/or dermatological compositions containing same and uses thereof | |
| Rawyler et al. | Cyclodextrins: a new tool for the controlled lipid depletion of thylakoid membranes | |
| FR2681868A1 (en) | New amphiphilic substances derived from cyclodextrins and their use in cosmetic compositions | |
| FR2838342A1 (en) | Cosmetic or dermatological compositions, e.g. for combating skin aging, containing extract of Sargassum muticum brown algae having e.g. antiradical and DNA protecting action | |
| WO2003075903A2 (en) | Use proline and its functional equivalentsfor quenching ros and/ or radicals | |
| EP4093370A1 (en) | Composition comprising hyaluronic acid and a polyol and/or carboxymethyl cellulose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CD | Change of name or company name | ||
| TP | Transmission of property | ||
| ST | Notification of lapse |